[Current Landscape of Sequential Treatment Strategy in Metastatic Urothelial Carcinoma]
{{output}}
In 2024, enfortumab vedotin plus pembrolizumab(EV+P)and nivolumab plus gemcitabine/cisplatin(Nivo+GC)were approved as first-line therapies for metastatic urothelial carcinoma(mUC), marking a major shift in treatment strategy.EV+P, in particular, demonstrated r... ...
